X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1247) 1247
chenodeoxycholic acid - therapeutic use (1006) 1006
male (623) 623
cholelithiasis - drug therapy (574) 574
female (558) 558
adult (401) 401
middle aged (397) 397
ursodeoxycholic acid - therapeutic use (383) 383
chenodeoxycholic acid (366) 366
animals (275) 275
aged (251) 251
gastroenterology & hepatology (229) 229
ursodeoxycholic acid (189) 189
bile acids and salts - metabolism (183) 183
chenodeoxycholic acid - analogs & derivatives (172) 172
cholelithiasis - therapy (172) 172
chenodeoxycholic acid - pharmacology (170) 170
cholesterol - metabolism (169) 169
bile acids (167) 167
chenodeoxycholic acid - adverse effects (158) 158
bile (157) 157
chenodeoxycholic acid - administration & dosage (148) 148
cholelithiasis - metabolism (147) 147
cholesterol (120) 120
deoxycholic acid - analogs & derivatives (112) 112
acids (111) 111
metabolism (108) 108
time factors (107) 107
liver (104) 104
liver - metabolism (98) 98
pharmacology & pharmacy (98) 98
deoxycholic acid (94) 94
liver - drug effects (92) 92
cholagogues and choleretics - therapeutic use (83) 83
rats (83) 83
bile - analysis (82) 82
recurrence (82) 82
clinical trials as topic (81) 81
chenodeoxycholic acid - metabolism (80) 80
bile - metabolism (79) 79
cholecystectomy (77) 77
bile-acids (76) 76
adolescent (75) 75
cholesterol - blood (75) 75
lithotripsy (75) 75
gallstones (74) 74
liver - pathology (73) 73
treatment outcome (73) 73
mice (71) 71
receptors, cytoplasmic and nuclear - agonists (71) 71
cholesterol - analysis (70) 70
receptors, cytoplasmic and nuclear - metabolism (69) 69
medicine, general & internal (68) 68
bile acids and salts - therapeutic use (67) 67
cholelithiasis - etiology (67) 67
drug therapy, combination (66) 66
nuclear receptor (65) 65
administration, oral (63) 63
fxr (63) 63
solubility (62) 62
obeticholic acid (59) 59
cholic acid (57) 57
research article (57) 57
care and treatment (56) 56
xanthomatosis, cerebrotendinous - drug therapy (56) 56
primary biliary-cirrhosis (54) 54
liver cirrhosis, biliary - drug therapy (53) 53
liver diseases (53) 53
gastroenterology and hepatology (52) 52
follow-up studies (50) 50
cholelithiasis - diagnostic imaging (49) 49
farnesoid-x-receptor (49) 49
lipid metabolism (49) 49
double-blind method (48) 48
drug evaluation (48) 48
triglycerides - blood (48) 48
bile acids and salts - analysis (47) 47
bile acids and salts - blood (47) 47
cerebrotendinous xanthomatosis (47) 47
cholelithiasis - surgery (47) 47
dose-response relationship, drug (47) 47
ursodeoxycholic acid - administration & dosage (47) 47
bile-acid (46) 46
cholestasis (46) 46
cirrhosis (46) 46
expression (46) 46
farnesoid x receptor (45) 45
physiological aspects (45) 45
surgery (45) 45
biochemistry & molecular biology (44) 44
medicine & public health (44) 44
clinical neurology (43) 43
disease (43) 43
gastrointestinal agents - therapeutic use (43) 43
liver function tests (43) 43
dissolution (42) 42
medicine (41) 41
ursodeoxycholic acid - adverse effects (41) 41
child (40) 40
fibrosis (40) 40
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1141) 1141
German (120) 120
French (72) 72
Japanese (30) 30
Italian (28) 28
Russian (23) 23
Spanish (22) 22
Dutch (9) 9
Czech (7) 7
Chinese (5) 5
Danish (5) 5
Polish (4) 4
Hungarian (3) 3
Norwegian (3) 3
Swedish (3) 3
Portuguese (2) 2
Croatian (1) 1
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2015, Volume 148, Issue 4, pp. 751 - 761.e8
Journal Article
Liver international, ISSN 1478-3231, 2016, Volume 37, Issue 5, pp. 634 - 647
.... Insulin resistance with an increased release of free fatty acids, oxidative stress and activation of inflammatory cytokines seem to be key features for disease progression... 
steatohepatitis | pharmacological treatment | fatty liver | fibrosis | VITAMIN-E | OBETICHOLIC ACID | AMERICAN ASSOCIATION | FATTY LIVER-DISEASE | PROLIFERATOR-ACTIVATED RECEPTOR | REDUCES FEATURES | PPAR AGONIST IVA337 | GASTROENTEROLOGY & HEPATOLOGY | TYPE-2 DIABETES-MELLITUS | BILE-ACIDS | STEAROYL-COENZYME | Hypoglycemic Agents - therapeutic use | Non-alcoholic Fatty Liver Disease - pathology | Humans | Insulin Resistance | Propionates - therapeutic use | Chenodeoxycholic Acid - analogs & derivatives | Disease Progression | Non-alcoholic Fatty Liver Disease - drug therapy | Randomized Controlled Trials as Topic | Non-alcoholic Fatty Liver Disease - complications | Antioxidants - therapeutic use | Thiazolidinediones - therapeutic use | Weight Loss | Chenodeoxycholic Acid - therapeutic use | Vitamin E - therapeutic use | Chalcones - therapeutic use | Liver Cirrhosis - pathology | Antioxidants | Medical research | Liver | Medicine, Experimental | Development and progression | Insulin resistance | Fatty acids | Health aspects | Liver cirrhosis | Oxidative stress | Cytokines | Complications | Therapeutic applications | Pathogenesis | Pioglitazone | Clinical trials | Homeostasis | Pharmacology | Inflammation | Insulin | Patients | Cirrhosis | Oxidation resistance | Diet | Vitamin E | Fibrosis | Tocopherol | Thiazolidinediones | Habits
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 7, pp. 631 - 643
In this 12-month, placebo-controlled trial involving patients with primary biliary cholangitis who had an inadequate response to ursodiol, treatment with obeticholic acid, a farnesoid X receptor... 
CHANGING NOMENCLATURE | PBC | FXR | MEDICINE, GENERAL & INTERNAL | PROGNOSIS | CIRRHOSIS | BIOCHEMICAL RESPONSE | SCALE | Liver Cirrhosis - etiology | Bile Acids and Salts - blood | Double-Blind Method | Humans | Middle Aged | Liver Cirrhosis, Biliary - drug therapy | Male | Chenodeoxycholic Acid - analogs & derivatives | Bone Density - drug effects | Chenodeoxycholic Acid - adverse effects | Fibroblast Growth Factors - blood | Chenodeoxycholic Acid - therapeutic use | Adult | Female | Aged | Liver Cirrhosis, Biliary - complications | Liver Cirrhosis, Biliary - blood | Alkaline Phosphatase - blood | Pruritus - chemically induced | Clinical trials | Ursodiol | Care and treatment | Usage | Dosage and administration | Cholangitis | Primary biliary cirrhosis | Alkaline phosphatase | Liver diseases | Syngeneic grafts | Liver | Bilirubin | Pruritus | Phosphatase | Patients | Cirrhosis | Allografts | Acids | Fibrosis | Drug therapy | Bile | Liver transplantation | Alkaline Phosphatase | Chenodeoxycholic Acid | Fibroblast Growth Factors | Gastroenterology and Hepatology | Bone Density | drug therapy | chemically induced | complications | Gastroenterologi | drug effects | Liver Cirrhosis | blood | Bile Acids and Salts | etiology | Biliary | analogs & derivatives | adverse effects | therapeutic use
Journal Article
Clinics in liver disease, ISSN 1089-3261, 05/2016, Volume 20, Issue 2, pp. 365 - 385
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2016, Volume 18, Issue 12, pp. 1217 - 1225
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2013, Volume 145, Issue 3, pp. 574 - 582.e1
Journal Article